Table of Contents
J. Clin. Med., Volume 7, Issue 4 (April 2018)
- Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
- You may sign up for e-mail alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Cover Story (view full-size image) Bruton’s tyrosine kinase (BTK) is a critical terminal enzyme in the B-cell antigen receptor (BCR) [...] Read more. Bruton’s tyrosine kinase (BTK) is a critical terminal enzyme in the B-cell antigen receptor (BCR) pathway. BTK activation has been implicated in the pathogenesis of certain B-cell malignancies. Targeting this pathway has emerged as a novel target in B-cell malignancies, of which ibrutinib is the first-in-class agent. Other BTK inhibitors (BTKi) are also under development. While the predominant action of BTKi is the blockade of the BCR pathway within malignant B-cells, increasing knowledge of off-target effects as well as a potential role for B-cells in the proliferation of solid malignancies is expanding the indication of BTKi into non-hematological malignancies. In addition to BTKi monotherapy, combination therapy strategies utilizing ibrutinib with established regimens and in combination with modern immunotherapy compounds are being explored. View this paper